Core Viewpoint - The company’s PCV13 vaccine recently received GMP certification from the Turkish drug regulatory authority, indicating that the product meets the necessary conditions for entry into the Turkish market, which is expected to further open up the Turkish market and lay a solid foundation for expansion into surrounding markets in the Middle East and Africa [1][2][3] Event - On July 1, the company announced that its wholly-owned subsidiary, Minhai Biotech, received GMP certification for its 13-valent pneumococcal conjugate vaccine (PCV13) from the Turkish drug regulatory authority, confirming that the production facilities, processes, quality control, and quality management systems comply with Turkey's stringent drug production quality management standards [2] Company Expansion - The company has been continuously advancing its overseas business expansion, having reached cooperation agreements with over ten countries regarding the registration, promotion, commercialization, and technology transfer of products such as PCV13, PPSV23, varicella live attenuated vaccine, and quadrivalent vaccine [3] - The first batch of PCV13 finished products is expected to be successfully exported to Indonesia by August 2024. The recent GMP certification from Turkey signifies that the product is now eligible for entry into the Turkish market, which may further open up the international market for PCV13 and contribute to the company's overseas revenue growth [3] Sales Performance - In Q1 2025, the company achieved operating revenue of 645 million yuan, a year-on-year increase of 42.85%. The net profit attributable to the parent company was 22 million yuan, a year-on-year decrease of 58.51%. The net profit excluding non-recurring gains and losses was 17 million yuan, a year-on-year increase of 17.56%. The revenue and net profit excluding non-recurring items increased mainly due to steady sales of PCV13 and hepatitis B vaccines, along with contributions from new products such as human diploid rabies vaccine and varicella vaccine [4] - The decline in net profit attributable to the parent company was primarily due to a decrease in non-recurring gains such as government subsidies [4] Future Outlook - The company is optimistic about maintaining steady growth in performance driven by the sales of conventional vaccine products in the second half of the year, as it actively strengthens terminal sales and optimizes channel inventory while promoting the market entry of new products [4] - The company forecasts operating revenues of 2.963 billion yuan, 3.446 billion yuan, and 3.816 billion yuan for 2025 to 2027, representing year-on-year growth rates of 11.8%, 16.3%, and 10.8%, respectively. The net profit attributable to the parent company is expected to be 209 million yuan, 381 million yuan, and 526 million yuan, with corresponding year-on-year growth rates of 3.4%, 82.6%, and 38.3% [5]

Core Viewpoint - Wang Zhentao, the actual controller of Kanghua Biological, plans to transfer the company's control, which may be a self-rescue move to alleviate financial pressure as both Kanghua Biological and Aokang International face development difficulties [1][2][4]. Company Overview - Kanghua Biological specializes in human vaccines, with its core product being the freeze-dried human rabies vaccine, the first of its kind in China [4][9]. - Aokang International, known as "China's first men's shoe stock," was founded by Wang Zhentao and has expanded into a diversified group covering shoes, vaccines, finance, and real estate [6][11]. Financial Performance - Kanghua Biological's net profit has declined for three consecutive years, with revenues of 14.47 billion, 15.77 billion, and 14.32 billion yuan from 2022 to 2024, and net profits of 5.98 billion, 5.09 billion, and 3.99 billion yuan respectively [9][10]. - In Q1 2025, Kanghua Biological reported a revenue of 1.38 billion yuan, down 55.7% year-on-year, and a net profit of 20.71 million yuan, down 86.15% [10]. - Aokang International's revenue has also decreased, with figures of 27.5 billion, 30.86 billion, and 25.39 billion yuan from 2022 to 2024, and net losses of 3.74 billion, 932.79 million, and 2.16 billion yuan respectively [11][12]. Shareholding and Control - Wang Zhentao directly holds 10.53% of Kanghua Biological and controls a total of 19% of the shares through Aokang Group [4][9]. - The high pledge ratio of Wang Zhentao's shares is concerning, with 89% of his shares in Kanghua Biological and 99% in Aokang International being pledged [16]. Market Reaction - Following the announcement of the potential control transfer, Kanghua Biological's stock surged by 16.2%, closing at 72.01 yuan per share, with a market capitalization of 9.574 billion yuan [4][9].

山东三元生物科技股份有限公司 章 程 二〇二五年七月 山东三元生物科技股份有限公 司 公 司章程 山东三元生物科技股份有限公司 公司章程 目 录 第一章 总 则 第一条 为维护山东三元生物科技股份有限公司（以下简称"公司"）、公司股 东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司治理准则》 （以下简称"《治理准则》"） 《上市公司章程指引》 （以下简称"《章 程指引》 "）《深圳证券交易所创业板股票上市规则》 （以下简称"《上市规则》"） 《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》和其他 有关规定，制订《山东三元生物科技股份有限公司章程》（以下简称"本章程"）。 第二条 公司系由滨州三元生物科技有限公司依法整体变更设立，滨州三元生 物科技有限公司的原有股东即为公司发起人。公司在滨州市工商行政管理部门注册 登记，取得营业执照，统一社会信用代码为 913716007986665561。 第三条 公司于 2021 年 12 月 23 日经深圳证券交易所审核并经中国证券 ...

Core Viewpoint - Wang Zhentao, the controlling shareholder of Kanghua Biological, is planning to transfer control of the company after five years of its listing, which may lead to a change in the company's controlling shareholder and actual controller [1][2]. Group 1: Company Control Change - On July 13, Kanghua Biological announced that Wang Zhentao is planning a change in the company's control, which may lead to a change in the controlling shareholder and actual controller [1][2]. - As of now, Wang Zhentao directly and indirectly holds 19.02% of Kanghua Biological's shares, with a market capitalization of approximately 96 billion yuan [2][7]. - The stock price of Kanghua Biological surged by 16% on July 11, prior to the announcement of the control change [2][3]. Group 2: Financial Performance - Kanghua Biological's financial performance has been under pressure, with a significant decline in net profit. The net profit for Q1 2025 dropped by over 86% to 20.71 million yuan [2][10]. - The company experienced rapid growth in its early years post-IPO, with net profits of 408 million yuan in 2020 and 829 million yuan in 2021, but has seen a continuous decline in profits since then [10][12]. - The decline in performance is attributed to reduced vaccine sales and increased market competition, with vaccine revenue accounting for over 90% of total revenue [2][9]. Group 3: Market Reactions and Future Outlook - The stock was suspended from trading starting July 14 to ensure fair information disclosure and avoid abnormal price fluctuations [3]. - Analysts speculate that the control transfer may involve a share transfer of over 10% to 15% of the shares [6]. - The estimated transaction value for the control transfer is expected to exceed 1 billion yuan, not considering any premium [8].

今日（7月14日），A股震荡盘整，三大指数涨跌不一，截至收盘，沪指涨0.27%，深证成指跌0.11%， 创业板指跌0.45%。沪深两市全天成交额合计1.46万亿元，较上一交易日缩量超2500亿元。 盘面上，制药板块走强，创新药、中药联袂拉涨，高纯度聚焦创新药产业链的港股通创新药ETF （520880）场内价格大涨1.67%，聚焦龙头药企的药ETF（562050）场内价格收涨0.9%，创上市以来新 高；高股息继续发力，800红利低波ETF（159355）、银行ETF（512800）双双收红。人工智能相关方 向继续上扬，重点布局国产AI产业链的科创人工智能ETF华宝（589520）场内价格收涨0.58%，日线两 连阳。下跌方面，稳定币、跨境支付等热门概念股集体下挫，金融科技ETF（159851）场内价格收跌 2.64%，失守五日线。 | 序号 代码 | | 涨跌幅 ▼ | | --- | --- | --- | | 1 - | 520880 港股通创新药ETF T+0 | 1.67% | | 2 | 562050 药ETF | 0.90% | | 3 | 159355 800红利低波ETF | 0.84% | | ...

成都欧林生物科技股份有限公司 董事、高级管理人员及控股股东买卖股票与沟通报备制度 第一章 总则 第一条 为加强对公司董事、高级管理人员（以下简称"董高"）及控股股东 持有及买卖本公司股票的管理，进一步明确办理程序，根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司董事和高级管理人员所持本公司股 份及其变动管理规则》《上市公司股东减持股份管理暂行办法（2025 年修订）》 《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人 员减持股份》等相关法律法规和《公司章程》的有关规定，结合公司实际情况， 制定本制度。 第二条 本制度适用于公司董事、高级管理人员及控股股东所持本公司股份 及其变动的管理。 第三条 董事、高级管理人员及控股股东开立多个证券账户的，对各证券账 户的持股合并计算；董事、高级管理人员及控股股东所持股份不单指登记在其名 下的本公司股份，其从事融资融券交易的，还包括记载在其信用账户内的本公司 股份。 第四条 公司董事、高级管理人员及控股股东在买卖公司股票及其衍生品种 前，应知悉并遵守有关法律法规、规范性文件中关于内幕交易、操纵市场、短线 交易、窗口期交易、限售期出售 ...

成都欧林生物科技股份有限公司 董事会议事规则 第一条 宗旨 为了完善成都欧林生物科技股份有限公司（以下简称"公司"）的法人治理结构，规范公 司董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》《上海证券交易所科创板股票上市规则》（以下简称《上市规则》） 及《成都欧林生物科技股份有限公司章程》（以下简称公司章程）等有关规定，制定本 规则。 第二条 董事会 公司依法设立董事会，是公司的法定代表机构、常设权力机构和决策机构，行使法律法 规、公司章程及股东会赋予的职权，并对股东会负责。 第三条 董事会会议 董事会会议是董事会议事的主要形式。董事按规定参加董事会会议是履行董事职责的基 本方式。 第四条 董事会成员构成 公司董事会由 7-9 名董事组成，其中职工代表董事 1 名，独立董事的比例不低于三分之 一，设董事长 1 人，可以设副董事长，董事长和副董事长由董事会以全体董事的过半数 选举产生、变更。 非职工代表董事由股东会选举或者更换，并可在任期届满前由股东会解除其职务。董事 任期 3 年。职 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-029 成都欧林生物科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 30 日 13 点 00 分 召开地点：成都高新区天欣路 99 号公司会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-027 成都欧林生物科技股份有限公司 关于公司董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鉴于成都欧林生物科技股份有限公司（以下简称"公司"）第六届董事会任 期届满，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》 等法律法规、规范性文件以及《成都欧林生物科技股份有限公司章程》（以下简 称"《公司章程》"）等规定，公司开展董事会换届选举工作，现就相关情况公 告如下： 一、董事会换届选举情况 公司于 2025 年 7 月 14 日召开第六届董事会第二十二次会议，审议通过了《关 于董事会换届选举暨提名第七届董事会非独立董事候选人的议案》以及《关于董 事会换届选举暨提名第七届董事会独立董事候选人的议案》。 经董事会提名委员会审查同意，公司董事会同意提名樊绍文先生、樊钒女士、 张鹏飞先生、陈爱民女士、余云辉先生为公司第六届董事会非独立董事候选人（简 历附后）；提名鞠佃文先生、陈正旭先生、段宏女士为公司第六届董事会独立董 事候选 ...

Core Viewpoint - The document outlines the management system for the temporary suspension and exemption of information disclosure by Chengdu Olin Biotechnology Co., Ltd, emphasizing compliance with relevant laws and regulations while ensuring the protection of state and commercial secrets [1][2]. Group 1: General Principles - The company aims to standardize the temporary suspension and exemption of information disclosure to ensure compliance with the Company Law, Securities Law, and other relevant regulations [1]. - Information disclosure obligations must be fulfilled accurately, completely, and timely, without misuse of suspension or exemption to mislead investors or engage in illegal activities [1][2]. Group 2: Scope of Suspension and Exemption - The company can exempt disclosure if the information involves state secrets or could violate confidentiality regulations, ensuring that no state secrets are leaked through any form of communication [2][3]. - Commercial secrets can be temporarily suspended or exempted from disclosure if they meet specific criteria, such as potential harm from disclosure or infringement of others' commercial secrets [2][3]. Group 3: Internal Management of Suspension and Exemption - The company must follow internal review procedures before implementing any suspension or exemption, maintaining records of the reasons and processes involved [4][5]. - A mechanism for accountability is established for any non-compliance with the disclosure regulations, with potential disciplinary actions for responsible personnel [5]. Group 4: Reporting and Documentation - The company is required to submit documentation of any suspended or exempted disclosures to the relevant regulatory bodies within ten days after the publication of periodic reports [4][5]. - Detailed records must be kept regarding the nature of the exempted information, the internal review process, and any potential impacts on the company or third parties [4][5].